FAZIO, CAROLINA
 Distribuzione geografica
Continente #
NA - Nord America 806
EU - Europa 633
AS - Asia 103
AF - Africa 2
SA - Sud America 1
Totale 1.545
Nazione #
US - Stati Uniti d'America 805
IE - Irlanda 163
GB - Regno Unito 122
IT - Italia 120
RU - Federazione Russa 61
CN - Cina 54
SE - Svezia 46
UA - Ucraina 32
SG - Singapore 27
DE - Germania 26
FR - Francia 24
ES - Italia 14
FI - Finlandia 13
VN - Vietnam 12
BE - Belgio 3
IN - India 3
CH - Svizzera 2
HR - Croazia 2
PL - Polonia 2
TR - Turchia 2
BO - Bolivia 1
CZ - Repubblica Ceca 1
GR - Grecia 1
HK - Hong Kong 1
IL - Israele 1
KG - Kirghizistan 1
MA - Marocco 1
MY - Malesia 1
PA - Panama 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
ZA - Sudafrica 1
Totale 1.545
Città #
Dublin 163
Fairfield 155
Southend 112
Woodbridge 83
Ashburn 67
Cambridge 63
Seattle 57
Wilmington 57
Houston 56
New York 36
Jacksonville 30
Chandler 29
Ann Arbor 25
Siena 24
Princeton 21
Singapore 19
Beijing 18
Shanghai 15
Málaga 13
Dong Ket 11
Helsinki 11
San Diego 11
San Mateo 11
Dearborn 6
Milan 6
Fremont 5
Nanjing 5
San Giovanni Valdarno 5
Hounslow 4
Labico 4
Palermo 4
Redwood City 4
Santa Clara 4
Venezia 4
Asciano 3
Boardman 3
Brussels 3
Empoli 3
Florence 3
Lavis 3
Moscow 3
Rome 3
Altamura 2
Chiusdino 2
Düsseldorf 2
Pistoia 2
Salerno 2
San Francisco 2
Sesto Fiorentino 2
Zagreb 2
Zurich 2
Arezzo 1
Ascoli Piceno 1
Athens 1
Bishkek 1
Bratislava 1
Brno 1
Changsha 1
Chiswick 1
Ferentino 1
Figline Valdarno 1
Guangzhou 1
Guiyang 1
Haikou 1
Hefei 1
Hong Kong 1
Jiaxing 1
Jinan 1
Johannesburg 1
Kilburn 1
La Paz 1
Lanzhou 1
London 1
Los Angeles 1
Madrid 1
Menderes 1
Mumbai 1
Ningbo 1
Norwalk 1
Orta di Atella 1
Phoenix 1
Reggio Calabria 1
Roseto Degli Abruzzi 1
Scarperia 1
Sollentuna 1
Stagno 1
Stockholm 1
Tel Aviv 1
Torino 1
Trieste 1
Wandsworth 1
Warsaw 1
Zhengzhou 1
Totale 1.222
Nome #
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 213
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 181
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 158
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 145
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 130
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 129
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017 120
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 112
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 103
ICOS expression as immunologic marker in immune activating monoclonal antibodies 75
“Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014 59
null 58
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 43
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study 37
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study 32
Totale 1.595
Categoria #
all - tutte 6.041
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.041


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020351 0 0 0 0 59 38 52 66 57 39 17 23
2020/2021363 15 36 26 40 51 31 15 45 14 42 13 35
2021/2022177 8 34 17 6 8 10 10 6 3 19 28 28
2022/2023192 14 12 31 15 12 34 8 15 21 15 9 6
2023/2024272 9 4 35 8 11 89 90 4 5 0 11 6
2024/2025103 16 15 49 19 4 0 0 0 0 0 0 0
Totale 1.595